EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenicity and Tolerability of a SARS-CoV-2 TNX-1800, a Live Recombinant Poxvirus Vaccine Candidate, in Syrian Hamsters and New Zealand White Rabbits

Mayanka Awasthi iD, Anthony Macaluso, Scott J Goebel, Erin Luea, Ryan S Noyce iD, Farooq Nasar, Bruce Daugherty, Sina Bavari, Seth Lederman iD

Viruses · 2023

DOI: 10.3390/v15102131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Mayanka Awasthi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tonix Pharmaceutical, Frederick, MD 21701, USA. Hauptthemen laut MEDLINE: COVID-19, Poxviridae. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tonix Pharmaceuticals Holding Corp.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TNX-1800 is a preclinical stage synthetic-derived live attenuated chimeric horsepox virus vaccine engineered to express the SARS-CoV-2 spike (S) gene. The objectives of this study were to assess the safety, tolerability, and immunogenicity of TNX-1800 administration in Syrian golden hamsters and New Zealand white rabbits. Animals were vaccinated at three doses via percutaneous inoculation. The data showed that the single percutaneous administration of three TNX-1800 vaccine dose levels was well tolerated in both hamsters and rabbits. At all dose levels, rabbits were more decerning regarding vaccine site reaction than hamsters. Lastly, no TNX-1800 genomes could be detected at the site of vaccination. Post-vaccination, all animals had anti-SARS-CoV-2 spike protein IgG specific antibody responses. These data demonstrate that TNX-1800 infection was limited, asymptomatic, and cleared by the end of this study, and a single dose was able to generate immune responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19PoxviridaeCricetinaeRabbitsAnimalsMesocricetusSARS-CoV-2Vaccines, AttenuatedVaccines, SyntheticAntibodies, ViralImmunoglobulin GSpike Glycoprotein, CoronavirusAntibodies, Neutralizing

Stichwörter der Autor:innen

IgGSARS-CoV-2TNX-1800antibody titerhorsepoximmunogenicityspike proteinvaccinevaccine platform

Substanzen

Vaccines, AttenuatedVaccines, SyntheticAntibodies, ViralImmunoglobulin GSpike Glycoprotein, CoronavirusAntibodies, Neutralizingspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Tonix Pharmaceutical, Frederick, MD 21701, USA.
  • Southern Research, Birmingham, AL 35205, USA.
  • Department of Medical Microbiology & Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2R3, Canada.
  • Tonix Pharmaceuticals, Chatham, NJ 07928, USA.
  • Tonix Pharmaceuticals, Dartmouth, MA 02745, USA.

ORCID-Profile: Mayanka Awasthi, Ryan S Noyce, Seth Lederman

Förderung

  • Tonix Pharmaceuticals Holding Corp

Zitieren

APA

Awasthi, M., Macaluso, A., Goebel, S. J., Luea, E., Noyce, R. S., Nasar, F., Daugherty, B., Bavari, S., & Lederman, S. (2023). Immunogenicity and Tolerability of a SARS-CoV-2 TNX-1800, a Live Recombinant Poxvirus Vaccine Candidate, in Syrian Hamsters and New Zealand White Rabbits. Viruses. https://doi.org/10.3390/v15102131

Vancouver

Awasthi M, Macaluso A, Goebel SJ, Luea E, Noyce RS, Nasar F, et al. Immunogenicity and Tolerability of a SARS-CoV-2 TNX-1800, a Live Recombinant Poxvirus Vaccine Candidate, in Syrian Hamsters and New Zealand White Rabbits. Viruses. 2023. doi:10.3390/v15102131

BibTeX
@article{Awasthi2023,
  author = {Awasthi, Mayanka and Macaluso, Anthony and Goebel, Scott J and Luea, Erin and Noyce, Ryan S and Nasar, Farooq and Daugherty, Bruce and Bavari, Sina and Lederman, Seth},
  title = {Immunogenicity and Tolerability of a SARS-CoV-2 TNX-1800, a Live Recombinant Poxvirus Vaccine Candidate, in Syrian Hamsters and New Zealand White Rabbits},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15102131}
}
Kostenlos starten →